Statistics for Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
Total visits
| views | |
|---|---|
| Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC | 3 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 1 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:2c39efa2-aa93-41a2-b4e1-aaff18d39461 | 25 |
| java.util.UUID:2ae12be5-2a3a-46e8-b3a4-938d91a1cf59 | 10 |
| java.util.UUID:ada99203-60a1-49cd-b5e9-7c140a5a0ea5 | 10 |
| Evans2022Augmenting-CCBY.pdf | 5 |
Top country views
| views | |
|---|---|
| United States | 2 |
| Japan | 1 |
Top city views
| views | |
|---|---|
| Franklin | 2 |
| Tokyo | 1 |